Clinical Trial: 18282

Trial Status: Open
Trial Type: Breast
Disease Type: Breast
Trial ID 18282
Sponsor ID

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician’s Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

Principal Investigator
Christina Brzezniak, DO
5 Locations

Locations

Alexandria Office

Arlington Office

Gainesville Office

Fairfax Office

Loudoun Office

Learn More About This Trial
Other Relevant Trials
Trial ID 22101
Sponsor ID J2J-MC-JZLH

“EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)”

Principal Investigator
Shruti Tiwari, MD
4 Locations
Trial ID 21462
Sponsor ID GLSI-21-01 “FLAMINGO-01”

“A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)”

Principal Investigator
Shruti Tiwari, MD
4 Locations